Joel Beatty
Stock Analyst at Baird
(4.44)
# 318
Out of 4,967 analysts
196
Total ratings
47.77%
Success rate
23.55%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $2.47 | +142.91% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $12.00 | -24.97% | 6 | Jul 8, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $125.60 | +15.45% | 7 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $25.69 | +20.67% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $19.77 | +21.40% | 5 | May 16, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $58 → $50 | $23.68 | +111.15% | 2 | May 13, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $705.91 | -3.67% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $15.45 | +87.70% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $52.43 | +25.88% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $129.66 | +19.54% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $123.47 | +31.21% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $29.40 | +39.46% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $3.71 | +169.54% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $9.13 | +75.25% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $11.24 | +42.35% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $44.73 | +63.22% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $20.54 | +55.79% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $39.50 | +89.87% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $9.98 | +10.22% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.65 | +324.24% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $59.09 | +10.00% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $32.03 | +124.79% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.65 | +14,445.45% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.47 | +206.12% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $9.11 | +174.42% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.29 | +3,008.81% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $16.11 | +73.81% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.98 | +708.08% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.84 | -32.07% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.68 | +2,526.87% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $25.68 | +125.86% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $25.48 | -5.81% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $16.70 | +7.78% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $1.95 | +207.69% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.01 | +459.44% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $447.00 | -60.85% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.73 | +195.98% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $18.16 | +494.71% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $57.49 | +35.68% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $9.18 | +989.32% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $15.18 | +690.51% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.47 | +12,868.30% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.32 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $7.55 | +98.68% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.46 | +26,169.70% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $7.95 | +138.99% | 3 | Nov 10, 2017 |
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $2.47
Upside: +142.91%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $12.00
Upside: -24.97%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $125.60
Upside: +15.45%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $25.69
Upside: +20.67%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $19.77
Upside: +21.40%
Dianthus Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $58 → $50
Current: $23.68
Upside: +111.15%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $705.91
Upside: -3.67%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $15.45
Upside: +87.70%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $52.43
Upside: +25.88%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $129.66
Upside: +19.54%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $123.47
Upside: +31.21%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $29.40
Upside: +39.46%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $3.71
Upside: +169.54%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $9.13
Upside: +75.25%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $11.24
Upside: +42.35%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $44.73
Upside: +63.22%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $20.54
Upside: +55.79%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $39.50
Upside: +89.87%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $9.98
Upside: +10.22%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.65
Upside: +324.24%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $59.09
Upside: +10.00%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $32.03
Upside: +124.79%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.65
Upside: +14,445.45%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.47
Upside: +206.12%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $9.11
Upside: +174.42%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.29
Upside: +3,008.81%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $16.11
Upside: +73.81%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.98
Upside: +708.08%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.84
Upside: -32.07%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.68
Upside: +2,526.87%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $25.68
Upside: +125.86%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $25.48
Upside: -5.81%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $16.70
Upside: +7.78%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $1.95
Upside: +207.69%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.01
Upside: +459.44%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $447.00
Upside: -60.85%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.73
Upside: +195.98%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $18.16
Upside: +494.71%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $57.49
Upside: +35.68%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $9.18
Upside: +989.32%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $15.18
Upside: +690.51%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.47
Upside: +12,868.30%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.32
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $7.55
Upside: +98.68%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.46
Upside: +26,169.70%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $7.95
Upside: +138.99%